Product Program year 2023 Source: CMS Open Payments

Cosela

Drug Oncology

Open in the dashboard

General payments

$547,981

3,385 payments

Research payments

$15,964,361

3,353 payments

Through program year 2023, $547,981 in general payments and $15,964,361 in research payments were reported against Cosela (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2023 General $494,031 3,370
2023 Research $5,159,041 1,320
2022 General $53,950 15
2022 Research $10,805,321 2,033

Breakdown

Who paid General payments · program years 2022–2023
  1. G1 Therapeutics, Inc. $547,981 3,385 payments
Top recipients General payments · program year 2023
  1. Martin Dietrich Hematology & Oncology · Rockledge, FL $69,086 14% · 44 payments
  2. Norman Sharpless Hematology & Oncology · Chapel Hill, NC $45,992 9% · 4 payments
  3. Abdur Shakir Internal Medicine · Mattoon, IL $35,943 7% · 34 payments
  4. Jason Porter Hematology & Oncology · Germantown, TN $29,779 6% · 23 payments
  5. Mark Socinski Hematology & Oncology · Orlando, FL $25,908 5% · 17 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2023.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2023
  1. Hematology & Oncology Internal Medicine $269,854 57% · 738 practitioners
  2. Internal Medicine $50,268 11% · 38 practitioners
  3. Medical Oncology Internal Medicine $37,370 8% · 230 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $29,845 6% · 318 practitioners
  5. Nurse Practitioner, Adult Health Nurse Practitioner $20,166 4% · 87 practitioners

The top 5 of 54 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2023
  1. Florida $117,677 24% · 386 recipients
  2. North Carolina $87,535 18% · 85 recipients
  3. Tennessee $56,201 11% · 89 recipients
  4. Illinois $48,608 10% · 169 recipients
  5. New York $23,489 5% · 90 recipients

The top 5 of 48 states; each share is of general payments naming this product in 2023 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to COSELA
Billing code Providers Services Paid by Medicare
Injection, trilaciclib, 1mg J1448 2 31,800 $131,655

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

3,385 general · 3,353 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record